{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:52:27Z","timestamp":1767135147348,"version":"build-2238731810"},"reference-count":23,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["ACR Open Rheumatology"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Gout is a type of painful inflammatory arthritis that affects patient health and quality of life, making remission a crucial goal. The Gout Hyperuricemia and Crystal\u2010Associated Disease Network (G\u2010CAN) recently proposed a standard definition for gout remission. Using adapted criteria from de Lautour et al and recent G\u2010CAN criteria, this post hoc analysis used existing data from the Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase (MIRROR) randomized controlled trial (NCT03994731) to determine potential gout remission rates in patients with pegloticase\u2010induced intensive urate\u2010lowering.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Based on the adapted gout remission criteria from de Lautour et al, remission was defined as meeting all of the following six criteria: resolution of \u22651 tophus, serum urate (SU) level &lt;6 mg\/dL, no gout flares in the previous three months, pain score \u22641 (10\u2010point scale), swollen joint count \u22641, and Physician Global Assessment of Gout score \u22641. An abbreviated three\u2010criteria definition, modeled after the G\u2010CAN definition, included gout flare, SU level, and tophus resolution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 145 patients received \u22651 dose of pegloticase (pegloticase with methotrexate, n = 96; pegloticase with placebo, n = 49), with 90 and 74 patients remaining on treatment through weeks 24 and 52, respectively. At weeks 24 and 52, 13.3% of patients (12 of 90) and 43.2% of patients (32 of 74) achieved gout remission using the six\u2010criteria definition, and 36.7% (33 of 90) and 70.3% of patients (52 of 74) achieved remission using the three\u2010criteria definition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Using the study full and simplified definitions, nearly half to three\u2010quarters of patients who remained on pegloticase for 52 weeks achieved gout remission. This novel analysis provides evidence that remission is possible in many patients with uncontrolled gout within one year of intensive, sustained urate\u2010lowering.<\/jats:p>\n                    <jats:p>\n                      <jats:boxed-text content-type=\"graphic\" position=\"anchor\">\n                        <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/acr270080-gra-0001-m.png\">\n                          <jats:alt-text>image<\/jats:alt-text>\n                        <\/jats:graphic>\n                      <\/jats:boxed-text>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr2.70080","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T12:29:13Z","timestamp":1755174553000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gout Remission With Pegloticase\u2010Induced Intensive Urate\u2010Lowering Therapy: A Post Hoc Clinical Trial Analysis"],"prefix":"10.1002","volume":"7","author":[{"given":"Yael","family":"Klionsky","sequence":"first","affiliation":[{"name":"Wake Forest University School of Medicine  Winston\u2010Salem North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina D.","family":"Torralba","sequence":"additional","affiliation":[{"name":"(current address: \u2022\u2022), Amgen Inc  Thousand Oaks California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Obermeyer","sequence":"additional","affiliation":[{"name":"(current address: \u2022\u2022), Amgen Inc  Thousand Oaks California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lissa","family":"Padnick\u2010Silver","sequence":"additional","affiliation":[{"name":"(current address: \u2022\u2022), Amgen Inc  Thousand Oaks California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon","family":"Lam","sequence":"additional","affiliation":[{"name":"Arthritis &amp; Osteoporosis Consultants of the Carolinas and Atrium Health Wake Forest Baptist  Charlotte North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"LaMoreaux","sequence":"additional","affiliation":[{"name":"(current address: \u2022\u2022), Amgen Inc  Thousand Oaks California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"e_1_2_8_2_1","volume-title":"Gout","author":"Fenando A","year":"2025"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2016.1221732"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20405"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22741"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-023-00565-x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209707"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2013.04.003"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00260-1"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24180"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000000000000221"},{"key":"e_1_2_8_12_1","article-title":"The Gout, Hyperuricemia and Crystal\u2010Associated Disease Network (G\u2010CAN) definition of clinical remission in gout","author":"Tabi\u2010Amponsah AD","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152555"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42335"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1782-x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2024.105715"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11578"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2024-eular.2570"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212046"},{"issue":"11","key":"e_1_2_8_20_1","first-page":"1256","article-title":"Dual\u2010energy computed tomography has additional prognostic value over clinical measures in gout including tophi: a systematic literature review","volume":"49","author":"Stauder SK","year":"2022","journal-title":"J Rheumatol"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.1025"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2024-eular.2063"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204463"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.09.007"}],"updated-by":[{"DOI":"10.1002\/acr2.70128","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000}}],"container-title":["ACR Open Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.70080","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:22:22Z","timestamp":1761121342000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr2.70080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1002\/acr2.70080"],"URL":"https:\/\/doi.org\/10.1002\/acr2.70080","archive":["Portico"],"relation":{},"ISSN":["2578-5745","2578-5745"],"issn-type":[{"value":"2578-5745","type":"print"},{"value":"2578-5745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"2025-04-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70080"}}